ALTIMMUNE, INC.

ALT · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Market Data

Price $2.64 +0.03 (+1.15%)

Market Cap—

P/E Ratio—

EPS$—

52W High$—

52W Low$—

Beta—

Data from Finnhub · Updated Jun 15, 2026